PENGARUH TERAPI ADJUVAN DEKSAMETASON SUBKONJUNGTIVA TERHADAP KADAR INTERLEUKIN-6 (IL-6) DAN TRANSFORMING GROWTH FACTOR BETA 2 (TGF-β2), DI CAIRAN VITREUS PADA PROLIFERATIVE VITREORETINOPATHY GRADE B-C (Studi Eksperimental pada Pasien Rhegmatogenous Retinal detachment di RSUD Dr. Soetomo)
| Main Author: | Tri Subekti, 011428016304 |
|---|---|
| Format: | Thesis NonPeerReviewed Book |
| Bahasa: | ind |
| Terbitan: |
, 2019
|
| Subjects: | |
| Online Access: |
http://repository.unair.ac.id/83472/1/PPDS.IKM.%2005-19%20Sub%20p%20Abstrak.pdf http://repository.unair.ac.id/83472/2/PPDS.IKM.%2005-19%20Sub%20p.pdf http://repository.unair.ac.id/83472/ http://lib.unair.ac.id |
Daftar Isi:
- Objective: To evaluate IL-6 and TGF-β2 levels in the vitreous of PVR grade B-C with rhegmatogenous retinal detachment patients that were given subconjunctival dexamethasone adjuvant therapy compared to the group who received no adjuvant therapy at RSUD Dr. Soetomo Surabaya. Material and Methods: In this experimental study, 36 patients were enrolled and randomly assigned to two groups: adjuvant subconjunctival dexamethasone 10 mg (treatment group: 20 patients) and no adjuvant therapy (control group: 16 patients). Group A (20 patients) was given adjuvant therapy with subconjunctival dexamethasone 10 mg as treatment group, and Group B (16 patients) was not given adjuvant therapy as control group. Dexamethasone 10 mg adjuvant therapy was given 5-6 hours before vitrectomy and vitreous samples were collected by pars plana primary vitrectomy. All vitreous samples were immediately frozen at - 80o C. Vitreous levels of IL-6 and TGF-β2 were measured using Human sandwich ELISA. The outcomes were analyzed using the Mann-Whitney test. Results: The mean intravitreal IL-6 level was 334.23 pg/ml in the treatment group and the mean intravitreal IL-6 level in the control group was 157.52 pg/ml. The mean intravitreal TGF-β2 level was 223.93 pg/ml in the treatment group and the mean intravitreal TGF-β2 level in the control group was 151.85 pg/ml. Conclusion: There was no significant differences between the reduction of IL-6 and TGF-β2 levels in the treatment group and the control group.